SG11202002088TA - Methods and compositions for treating chronic lung diseases - Google Patents

Methods and compositions for treating chronic lung diseases

Info

Publication number
SG11202002088TA
SG11202002088TA SG11202002088TA SG11202002088TA SG11202002088TA SG 11202002088T A SG11202002088T A SG 11202002088TA SG 11202002088T A SG11202002088T A SG 11202002088TA SG 11202002088T A SG11202002088T A SG 11202002088TA SG 11202002088T A SG11202002088T A SG 11202002088TA
Authority
SG
Singapore
Prior art keywords
compositions
methods
treating chronic
lung diseases
chronic lung
Prior art date
Application number
SG11202002088TA
Other languages
English (en)
Inventor
Norman Barton
Alexandra Mangili
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of SG11202002088TA publication Critical patent/SG11202002088TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1754Insulin-like growth factor binding proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/30Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11202002088TA 2017-09-11 2018-09-11 Methods and compositions for treating chronic lung diseases SG11202002088TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762557113P 2017-09-11 2017-09-11
PCT/US2018/050427 WO2019051474A1 (fr) 2017-09-11 2018-09-11 Procédés et compositions pour traiter des maladies pulmonaires chroniques

Publications (1)

Publication Number Publication Date
SG11202002088TA true SG11202002088TA (en) 2020-04-29

Family

ID=63794620

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002088TA SG11202002088TA (en) 2017-09-11 2018-09-11 Methods and compositions for treating chronic lung diseases

Country Status (19)

Country Link
US (2) US20190151411A1 (fr)
EP (1) EP3681602A1 (fr)
JP (2) JP2020533344A (fr)
KR (1) KR20200097679A (fr)
CN (1) CN111432881A (fr)
AU (1) AU2018328827A1 (fr)
BR (1) BR112020004760A2 (fr)
CA (1) CA3075482A1 (fr)
CL (1) CL2020000597A1 (fr)
CO (1) CO2020004244A2 (fr)
EA (1) EA202090705A1 (fr)
EC (1) ECSP20055797A (fr)
IL (1) IL273174A (fr)
MX (1) MX2020002744A (fr)
PE (1) PE20201166A1 (fr)
PH (1) PH12020500489A1 (fr)
SG (1) SG11202002088TA (fr)
WO (1) WO2019051474A1 (fr)
ZA (1) ZA202001568B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3194764A1 (fr) * 2020-10-19 2022-04-28 Oak Hill Bio Limited Compositions appropriees pour une utilisation chez des nouveau-nes
WO2023213908A1 (fr) * 2022-05-04 2023-11-09 Oak Hill Bio Limited Polythérapie pour nourrissons prématurés
WO2023242440A1 (fr) * 2022-06-17 2023-12-21 Oak Hill Bio Limited Traitement des poumons chez les nourrissons

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
DE3881801T2 (de) 1987-04-06 1993-12-23 Celtrix Pharma Menschliche somatomedin-träger-protein-untereinheiten und verfahren zu ihrer herstellung.
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
JPH03504597A (ja) 1988-04-12 1991-10-09 シナージェン,インコーポレーテッド インスリン様成長因子活性の強化および阻害方法
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
WO1993023067A1 (fr) 1992-05-08 1993-11-25 Thomas Jefferson University Analogues du facteur igf-1
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
DE60143858D1 (de) * 2000-11-28 2011-02-24 Premacure Ab Reduzierung DES RISIKOS FÜR KOMPLIKATIONEN BEI FRÜHGEBURTEN
WO2008130315A1 (fr) * 2007-04-18 2008-10-30 Premacure Ab Procédé et produit pour le traitement et/ou la prévention des complications liées à la prématurité

Also Published As

Publication number Publication date
CL2020000597A1 (es) 2020-12-04
ZA202001568B (en) 2023-09-27
EP3681602A1 (fr) 2020-07-22
US20190151411A1 (en) 2019-05-23
CA3075482A1 (fr) 2019-03-14
KR20200097679A (ko) 2020-08-19
PE20201166A1 (es) 2020-10-28
US20220088132A1 (en) 2022-03-24
CN111432881A (zh) 2020-07-17
IL273174A (en) 2020-04-30
JP2020533344A (ja) 2020-11-19
BR112020004760A2 (pt) 2020-09-15
JP2023145646A (ja) 2023-10-11
WO2019051474A1 (fr) 2019-03-14
EA202090705A1 (ru) 2020-06-11
MX2020002744A (es) 2020-10-01
CO2020004244A2 (es) 2020-05-29
ECSP20055797A (es) 2020-10-30
AU2018328827A1 (en) 2020-04-02
PH12020500489A1 (en) 2021-02-22

Similar Documents

Publication Publication Date Title
IL304820A (en) Preparations and methods for the treatment of cancer
EP3319976A4 (fr) Compositions et procédés pour traiter des maladies pulmonaires et des lésions pulmonaires
SG11201705093UA (en) Composition for treating il-6-related diseases
PT3377516T (pt) Composição para o tratamento do cancro
HK1254432A1 (zh) 用於治療纖維性疾病的方法和組合物
EP3612215A4 (fr) Compositions et procédés pour le traitement d'inflammation pulmonaire
IL290150A (en) Compounds and methods for treating chronic pain
IL269158A (en) Preparations and methods for the treatment of inflammatory diseases
EP3139928A4 (fr) Compositions d'anordrine et méthodes de traitement de maladies
SG10201913400QA (en) Methods for treating lung disorders
IL256523A (en) Compositions and methods for treating cancer
EP3110446A4 (fr) Procédés et compositions pour le traitement de maladies associées à siglec-8
IL255079A0 (en) Methods of treating lung cancer
ZA201605492B (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
IL261010B (en) Compositions and methods for treating chronic wounds
EP3322406A4 (fr) Méthodes et compositions transpapillaires pour le traitement des affections mammaires
EP3262065C0 (fr) Procédés et compositions de traitement des dystroglycanopathies
SG11202002088TA (en) Methods and compositions for treating chronic lung diseases
IL255638A (en) Compositions and methods for treating cancer
HK1244782A1 (zh) 用於治療疾病和病癥的組合物和方法
IL272945A (en) Local preparations and methods of treatment
HK1251490A1 (zh) 用於免疫介導的癌症治療的組合物和方法
HK1250958A1 (zh) 用於治療癌症的組合物和方法
EP3463422A4 (fr) Compositions et méthodes pour traiter les maladies métaboliques
EP3273965A4 (fr) Composition et procédés de traitement de maladie rénale chronique